Marija DİMİSHKOVSKA, Vjosa Mulliqi KOTORİ, Zoran GUCEV, Svetlana KOCHEVA, Momir POLENAKOVİC, Dijana PLASESKA KARANFİLSKA

Novel Founder Mutation in FANCA Gene (c.3446_3449dupCCCT) Among Romani Patients from the Balkan Region

Background: Fanconi anemia is a rare autosomalrecessive or X-linked disorder characterised by clinicaland genetic heterogeneity. Most fanconi anemiapatients harbour homozygous or double heterozygousmutations in the FANCA (60-65%), FANCC (10-15%), FANCG (~10%) or FANCD2 (3-6%) genes.We have already reported the FANCA variant c.190–256_283+1680del2040dupC as a founder mutationamong Macedonian fanconi anemia patients of Gypsylikeethnic origin. Here, we present a novel FANCAmutation in two patients from Macedonia and Kosovo.Case Report: The novel FANCA mutationc.3446_3449dupCCCT was identified in twofanconi anemia patients with Romany ethnicity; a2-year-old girl from Macedonia who is a compoundheterozygote for a previously reported FANCA c.190-256_283+1680del2040dupC and the novel mutation anda 10-year-old girl from Kosovo who is a homozygotefor the novel FANCA c.3446_3449dupCCCT mutation.The novel mutation is located in exon 35 in the FAAP20-binding domain which plays a crucial role in the FANCAFAAP20interaction and is required for integrity of thefanconi anemia pathway.Conclusion: The finding of the FANCAc.3446_3449dupCCCT mutation in two unrelated FApatients with Romani ethnicity from Macedonia andKosovo suggests it is a founder mutation in the Romanipopulation living in the Balkan region.

PDF

___

1. Tsangaris E, Klaassen R, Fernandez CV, Yanofsky R, Shereck E, Champagne J, et al. Genetic analysis of inherited bone marrow failure syndromes from one prospective, comprehensive and population-based cohort and identification of novel mutations. J Med Genet 2011;48:618-28.
2. Giri N, Batista DL, Alter BP, Stratakis CA. Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab 2007;92:2624-31.
3. Gille JJ, Floor K, Kerkhoven L, Ameziane N, Joenje H, de Winter JP. Diagnosis of Fanconi Anemia: Mutation Analysis by Multiplex LigationDependent Probe Amplification and PCR-Based Sanger Sequencing. Anemia 2012;2012:603253.
4. Faivre L, Guardiola P, Lewis C, Dokal I, Ebell W, Zatterale A, et al. Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. Blood 2000;96:4064-70.
5. Castella M, Pujol R, Callen E, Trujillo JP, Casado JA, Gille H, et al. Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood 2011;117:3759-69.
6. Madjunkova S, Kocheva SA and Plaseska-Karanfilska D. Fanconi anemia founder mutation in Macedonian patients. Acta Haematol 2014;132:15- 21.
7. Zemojtel T, Köhler S, Mackenroth L, Jager M, Hecht J, Krawitz P, et al. Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome. Sci Transl Med 2014;6:252ra123.
8. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 2010;362:1909-19.
9. Leung JW, Wang Y, Fong KW, Huen MS, Li L, Chen J. Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair. Proc Natl Acad Sci USA 2012;109:4491-6.
10. Ali AM, Pradhan A, Singh TR, Du C, Li J, Wahengbam K, et al. FAAP20: a novel ubiquitin-binding FA nuclear core-complex protein required for functional integrity of the FA-BRCA DNA repair pathway. Blood 2012;119:3285-94.